Impact BioMedical Plunges 27.33% Amid Merger Buzz

On June 24, 2025, Impact BioMedical experienced a significant drop of 27.33% in pre-market trading, marking a notable shift in its stock performance.

Impact BioMedical's recent merger with Dr. Ashleys Limited has been a major catalyst for its stock price movements. The merger, formalized through a share exchange agreement, involves Dr. Ashleys acquiring Impact BioMedical through a reverse merger. This strategic move has ignited substantial market interest, with the stock surging by over 300% in recent trading sessions. The merger is expected to create a newly formed combined entity, potentially driving future growth and innovation for the company.

The announcement of the merger has been met with enthusiasm from investors, who see the potential for significant gains. The merger agreement, signed on June 21, 2025, has set the stage for a transformative period for Impact BioMedical, as it integrates with Dr. Ashleys to leverage synergies and expand its market presence. The stock's performance reflects the market's optimism about the merger's potential to drive long-term value for shareholders.